Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen

Abstract

In this pilot trial, the antiemetic efficacy and tolerability of an all-oral antiemetic combination in the prevention of both acute and delayed nausea and vomiting following high-dose cisplatin was evaluated. Fifty-two patients receiving cisplatin (median dose 100 mg/m 2 ) were entered. Patients received (1) 60 min prior to cisplatin: prochlorperazine spansule 15 mg, dexamethasone 20 mg, granisetron 2 mg; (2) 12 h after cisplatin: prochlorperazine spansule 15 mg, dexamethasone 10 mg; (3) on days 2 and 3: prochlorperazine spansule 15 mg b.i.d., dexamethasone 8 mg b.i.d.; (4) on days 4 and 5: dexamethasone 4 mg b.i.d. All antiemetics were administered orally. The study period was the 120 h after cisplatin administration. The primary efficacy end-point was complete control (no vomiting, retching or antiemetic rescue) of delayed emesis (24-120 h after cisplatin). Complete control of de-

Population pharmacokinetics of cisplatin after 120-h infusion: application to routine adaptive control with feedback

“…However, the pharmacokinetic parameters calculated with the Bayesian‐based estimation were in agreement with the data from the literature (7). Finally, various toxic effects have been reported in many studies in which cisplatin was given at doses above 100 mg/m 2 (22–24). In this respect, the absence of toxicity observed in the present study (data not shown) was very promising as it suggests that drug monitoring of cisplatin was efficient enough to avoid toxicity in patients undergoing 5‐day infusion of this drug.…”